A critical analysis of prognostic factors in North American patients with human T-cell lymphotropic virus type-1-associated adult T-cell leukemia/lymphoma: a multicenter clinicopathologic experience and new prognostic score.

Autor: Phillips AA, Shapira I, Willim RD, Sanmugarajah J, Solomon WB, Horwitz SM, Savage DG, Bhagat G, Soff G, Zain JM, Alobeid B, Seshan VE, O'Connor OA

Publikováno v: Cancer (0008543X); 7/15/2010, Vol. 116 Issue 14, p3438-3446, 9p

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas.

Autor: Bhansali RS; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Ellin F; Department of Internal Medicine, Kalmar County Hospital, Kalmar, Sweden., Relander T; Department of Clinical Sciences Lund, Section for Oncology and Pathology, Lund University, Lund, Sweden.; Department of Oncology, Skane University Hospital, Lund, Sweden., Cao M; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Li W; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA., Long Q; Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia, PA., Ganesan N; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Stuver R; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Horwitz SM; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Wudhikarn K; Division of Hematology, Mayo Clinic, Rochester, MN.; Division of Hematology and Center of Excellence in Translational Hematology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand., Hwang SR; Division of Hematology, Mayo Clinic, Rochester, MN., Bennani NN; Division of Hematology, Mayo Clinic, Rochester, MN., Chavez J; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Sokol L; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Saeed H; Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL., Duan F; Department of Medicine, Christiana Care, Newark, DE., Porcu P; Division of Hematologic Malignancies, Thomas Jefferson University, Philadelphia, PA., Pullarkat P; Department of Medicine, Massachusetts General Hospital, Boston, MA., Mehta-Shah N; Division of Hematology/Oncology, Department of Medicine, Washington University in St. Louis, St. Louis, MO., Zain JM; Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA., Ruiz M; Divison of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Brammer JE; Divison of Hematology, The Ohio State University James Comprehensive Cancer Center, Columbus, OH., Prakash R; Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Iyer SP; Department of Lymphoma-Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX., Olszewski AJ; Division of Hematology/Oncology, Brown University, Providence, RI., Major A; Division of Hematology, University of Colorado Cancer Center, Aurora, CO., Riedell PA; Section of Hematology/Oncology, The University of Chicago, Chicago, IL., Smith SM; Section of Hematology/Oncology, The University of Chicago, Chicago, IL., Goldin C; Department of Hematology and Oncology, Ochsner MD Anderson Cancer Center, Jefferson, LA., Haverkos B; Division of Hematology, University of Colorado Cancer Center, Aurora, CO., Hu B; Department of Hematologic Oncology, Atrium Health, Levine Cancer Institute, Wake Forest School of Medicine, Charlotte, NC., Zhuang TZ; Winship Cancer Institute at Emory University, Decatur, GA., Allen PB; Winship Cancer Institute at Emory University, Decatur, GA., Toama W; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Janakiram M; Division of Hematology, Oncology and Transplantation, University of Minnesota, Minneapolis, MN., Brooks TR; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Jagadeesh D; Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH., Hariharan N; Division of Blood and Bone Marrow Transplantation, University of California San Diego Moores Cancer Center, San Diego, CA., Goodman AM; Division of Blood and Bone Marrow Transplantation, University of California San Diego Moores Cancer Center, San Diego, CA., Hartman G; Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY., Ghione P; Department of Medicine, Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NY., Fayyaz F; Division of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY., Rhodes JM; Division of Hematology/Oncology, Northwell Health Cancer Institute, New Hyde Park, NY., Chong EA; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Gerson JN; Division of Hematology/Oncology, University of Vermont Cancer Center, Burlington, VT., Landsburg DJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Nasta SD; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Schuster SJ; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Svoboda J; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA., Jerkeman M; Department of Clinical Sciences Lund, Section for Oncology and Pathology, Lund University, Lund, Sweden.; Department of Oncology, Skane University Hospital, Lund, Sweden., Barta SK; Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA.

Publikováno v: Blood advances [Blood Adv] 2024 Jul 09; Vol. 8 (13), pp. 3507-3518.

Aggressive T-cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management.

Autor: Ong SY; Department of Hematology/Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California, USA.; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Zain JM; Department of Hematology/Hematopoietic Cell Transplantation, City of Hope Medical Center, Duarte, California, USA.

Publikováno v: American journal of hematology [Am J Hematol] 2024 Mar; Vol. 99 (3), pp. 439-456. Date of Electronic Publication: 2024 Feb 02.

Final results of a phase II study of CHOEP plus lenalidomide as initial therapy for patients with stage II-IV peripheral T-cell lymphoma.

Autor: Stuver R; Memorial Sloan Kettering Cancer Center, Manhattan, New York, USA., Horwitz SM; Memorial Sloan Kettering Cancer Center, Manhattan, New York, USA., Advani RH; Stanford University, Stanford, California, USA., Vose JM; University of Nebraska Medical Center, Omaha, Nebraska, USA., Lee HJ; MD Anderson Cancer Center, Houston, Texas, USA., Mehta-Shah N; Washington University in St. Louis, St. Louis, Missouri, USA., Zain JM; City of Hope, Duarte, California, USA., Haverkos B; University of Colorado, Boulder, Colorado, USA., Lechowicz MJ; Emory University, Atlanta, Georgia, USA., Moskowitz AJ; Memorial Sloan Kettering Cancer Center, Manhattan, New York, USA., Pham LQ; Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA., Leyden E; University of Nebraska Medical Center, Omaha, Nebraska, USA., Ansell SM; Mayo Clinic, Rochester, Minnesota, USA., Lunning MA; University of Nebraska Medical Center, Omaha, Nebraska, USA.

Publikováno v: British journal of haematology [Br J Haematol] 2023 Aug; Vol. 202 (3), pp. 525-529. Date of Electronic Publication: 2023 May 22.